This week, FDA commissioner Scott Gottlieb, MD, announced that the agency’s Center for Drug Evaluation and Research (CDER) and the Office of Regulatory Affairs (ORA) are implementing a new agreement to integrate drug review programs with facility evaluations and inspections.
This week, FDA commissioner Scott Gottlieb, MD, announced that the agency’s Center for Drug Evaluation and Research (CDER) and the Office of Regulatory Affairs (ORA) are implementing a new agreement to integrate drug review programs with facility evaluations and inspections. The new strategy is intended to make better use of expertise and resources within the agency.
The FDA’s concept of operations for the agreement between the CDER and ORA aims to help the agency better handle the growing complexity of the pharmaceutical landscape by ensuring consistency, efficiency, and transparency in its facility evaluations and decision-making. It seeks to define clear roles for staff, improve operational capacity, enhance access to facility and regulatory decision information, and meet user fee commitments.
A key feature of the concept of operations is the establishment of Integrated Quality Assessment (IQA) teams. These teams are led by an application technical lead and managed by a regulatory business project manager. The leaders will oversee a drug substance reviewer, a drug product reviewer, a process/facility assessor, and ORA representatives (for preapproval inspections). Additional roles may be added if necessary. These teams are intended to align field and review staff in order to better share information and to make closer considerations of all elements of risk.
The concept of operations addresses the following types of evaluations and inspections:
The new concept of operations follows the FDA’s May announcement of its structural realignment of the ORA. The program alignment created a new organizational model in which the entire reporting chain for the organization’s inspection and compliance staff specialize in a particular commodity. Previously, the ORA had a geographic-based model in which employees conducted work in a variety of program areas, regardless of their specialties.
In announcing the new concept of operations, Gottlieb said, “This agreement will help make inspectional issues less likely to cause approval delays or prolong the time it takes to get important products to patients who can benefit from them.” Gottlieb also suggested that other operations in the FDA could be restructured as well, saying “we’ll continue to build on the opportunities enabled by closer coordination across our functions. We’ll leverage the new efficiency that it offers.”
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.